Prognostic significance of preoperative lymphocyte to monocyte ratio in patients with signet ring gastric cancer

Table 1 Baseline data and pathological features of the study participants

Characteristics	n (%)
Gender
Male	117 (55.19)
Female	95 (44.81)
Tumor site
Upper third	5 (2.36)
Middle third	58 (27.36)
Lower third	149 (70.28)
pT
pT1-2	79 (37.26)
pT3-4	133 (62.74)
pN
pN0	94 (44.34)
pN1-3	118 (55.66)
pTNM stage
Ⅰ/Ⅱ	117 (55.19)
Ⅲ	95 (44.81)
Resection scope
Distal stomach	167 (78.78)
Total stomach	45 (21.23)
Survival status
Survival	125 (58.96)
Dead	87 (41.04)

Table 2 Receiver operating characteristic curve analysis results of predictors

Variables	AUC (95%CI)	P value	Cut-off value	Sensitivity	Specificity
Age	0.589 (0.509-0.669)	0.028	55.5	0.494	0.728
PLR	0.589 (0.511-0.666)	0.028	124.63	0.586	0.608
LMR	0.590 (0.512-0.669)	0.025	3.83	0.54	0.632
ALB	0.618 (0.540-0.696)	0.004	38.95	0.414	0.792
PNI	0.644 (0.567-0.721)	< 0.001	49.85	0.632	0.608
FIB	0.624 (0.547-0.701)	0.002	3.115	0.655	0.648
CEA	0.632 (0.556-0.708)	0.001	1.455	0.471	0.744

PLR: Platelet to lymphocyte ratio; LMR: Lymphocyte to monocyte ratio; ALB: Albumin; PNI: Prognostic nutritional index; FIB: Fibrinogen; CEA: Carcinoembryonic antigen; AUC: Area under the curve.

Table 3 Relationship between baseline data, pathological features and 5-year survival rate

Group	Survival status		5-OS (%)	χ2	P value
	Survival (n)	Dead (n)
Gender				1.27	0.26
Male	73	44	62.39
Female	52	43	54.74
Tumor site				3.556	0.169
Upper third	1	4	20
Middle third	33	25	56.9
Lower third	91	58	61.07
pT				49.726	< 0.001
pT1-2	71	8	89.87
pT3-4	54	79	40.6
pN				30.269	< 0.001
pN0	75	19	79.79
pN1-3	50	68	42.37
pTNM stage				49.322	< 0.001
Ⅰ/Ⅱ	94	23	80.34
Ⅲ	31	64	32.63
Resection scope				8.489	0.004
Distal stomach	107	60	64.07
Total stomach	18	27	40

OS: Overall survival.

Table 4 Relationship between indicators and survival status

Variables	Survival	Dead	t/Z value	P value
Age	50 ± 10.82	53 ± 11.65	-2.213	0.028
CEA	0.90 (0.58, 1.48)	1.21 (0.75, 2.35)	-3.265	0.001
NLR	1.82 (1.30, 2.43)	2.05 (1.45, 2.71)	-1.668	0.095
PLR	118.33 (99.41, 150.18)	130.59 (108.10, 162.00)	-2.196	0.028
LMR	4.20 (3.40, 5.67)	3.80 (2.80, 5.00)	-2.226	0.026
SII	392.36 (275.38, 565.21)	448.00 (311.67, 600.71)	-1.391	0.164
PT	12.40 (11.96, 12.90)	12.30 (12.00, 12.70)	-1.114	0.265
INR	0.97 (0.93, 1.02)	0.95 (0.93, 0.99)	-1.728	0.084
APTT	32.71 ± 4.16	31.90 ± 3.98	1.425	0.156
TT	17.55 ± 1.73	17.66 ± 1.85	-0.424	0.672
FIB	2.93 (2.56, 3.42)	3.29 (2.81, 3.80)	-3.065	0.002
ALB (g/L)	41.79 ± 3.83	40.09 ± 4.72	2.854	0.005
GLB (g/L)	26.00 (23.80, 29.40)	25.20 (22.80, 28.50)	-1.356	0.175
AGR	1.58 (1.41, 1.80)	1.56 (1.40, 1.75)	-0.716	0.474
PNI	51.11 ± 4.95	48.21 ± 6.15	3.789	< 0.001

CEA: Carcinoembryonic antigen; NLR: Neutrophil to lymphocyte ratio; PLR: Platelet to lymphocyte ratio; LMR: Lymphocyte to monocyte ratio; SII: Systemic immune inflammation index; PT: Prothrombin time; INR: International normalized ratio; APTT: Activated partial thromboplastin time; TT: Thrombin time; FIB: Fibrinogen; ALB: Albumin; GLB: Globulin; AGR: Albumin to globulin ratio; PNI: Prognostic nutritional index.

Table 5 Grouping of predictors

		Survival (n)	Dead (n)	5-OS (%)	Total
Age	< 56	91	44	67.41	135
	≥ 56	34	43	44.16	77
CEA (ng/mL)	< 1.455	93	46	66.91	139
	≥ 1.455	32	41	43.84	73
PLR	< 124.63	76	36	67.86	112
	≥ 124.63	49	51	49	100
LMR	< 3.83	81	30	72.97	111
	≥ 3.83	44	57	43.56	101
ALB (g/L)	< 38.95	26	36	41.94	62
	≥ 38.95	99	51	66	150
PNI	< 49.85	49	55	47.12	104
	≥ 49.85	76	32	70.37	108
FIB (g/L)	< 3.115	46	47	49.46	93
	≥ 3.115	79	40	66.39	119

OS: Overall survival; CEA: Carcinoembryonic antigen; PLR: Platelet to lymphocyte ratio; LMR: Lymphocyte to monocyte ratio; ALB: Albumin; PNI: Prognostic nutritional index; FIB: Fibrinogen.